Testicular pain following initiation of elexacaftor/tezacaftor/ivacaftor in males with cystic fibrosis.

Elexacaftor/tezacaftor/ivacaftor (Trikafta) was approved by the Food and Drug Administration in October 2019 for treatment of cystic fibrosis (CF) in patients 12 years and older with at least one F508del mutation in the CFTR protein. There were no documented reports of testicular pain during clinical trials. In this case series, we discuss 7 males between 17 and 39 years of age who reported testicular pain or discomfort within the first two weeks of starting therapy. The precise mechanism of this side effect is unknown, but it may be related to restoration of CFTR function in the male reproductive tract. All patients experienced resolution of this side effect within a week after onset, regardless of the management, except for one. Further research is needed to determine short- and long-term impact of this drug on male fertility. Until more data is available, the authors recommend counseling patients on contraceptive options.

• Publication year

  2020

• Venue

  Journal of Cystic Fibrosis

• Publication date

  2020-05-26

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.jcf.2020.04.017PMID 32471772
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The Extrapulmonary Effects of Cystic Fibrosis Transmembrane Conductance Regulator Modulators in Cystic Fibrosis

  2020cited by this paper
• Congenital bilateral absence of the vas deferens as an atypical form of cystic fibrosis: reproductive implications and genetic counseling

  2018cited by this paper
• Normal vas deferens in fetuses with cystic fibrosis.

  1997cited by this paper

• "Side versus adverse effects of elexacaftor/tezacaftor/ivacaftor therapy in people with CF".

  2026cites this paper
• Photoaffinity Ligand of Cystic Fibrosis Corrector VX-445 Identifies SCCPDH as an Off-Target

  2025cites this paper
• Heterogeneity in Reported Side Effects Following Initiation of Elexacaftor‐Tezacaftor‐Ivacaftor: Experiences at a Quaternary CF Care Center

  2024cites this paper
• Differential distribution of ivacaftor and its metabolites in plasma and human airway epithelia.

  2024cites this paper
• Diverse role, structural trends, and applications of fluorinated sulphonamide compounds in agrochemical and pharmaceutical fields

  2024cites this paper
• Elexacaftor–tezacaftor–ivacaftor for cystic fibrosis with Phe508del mutation: Evidence from randomized controlled trials

  2024cites this paper
• Cystic Fibrosis Modulator Therapies: Bridging Insights from CF to other Membrane Protein Misfolding Diseases

  2024cites this paper
• “Shifting sands in cystic fibrosis”: impacts of CFTR modulators on reproductive health in people with cystic fibrosis and challenges related to in utero exposure

  2024cites this paper
• Pregnancy in Cystic Fibrosis—Past, Present, and Future

  2023cites this paper
• Trials and tribulations of highly effective modulator therapies in cystic fibrosis.

  2023cites this paper
• Post-approval studies with the CFTR modulators Elexacaftor-Tezacaftor—Ivacaftor

  2023cites this paper
• Efficacy and Safety of Elexacaftor-Tezacaftor-Ivacaftor in the Treatment of Cystic Fibrosis: A Systematic Review

  2023cites this paper
• Elexacaftor-Tezacaftor-Ivacaftor: A Life-Changing Triple Combination of CFTR Modulator Drugs for Cystic Fibrosis

  2023cites this paper
• Elexacaftor/VX-445–mediated CFTR interactome remodeling reveals differential correction driven by mutation-specific translational dynamics

  2023cites this paper
• Therapeutic Drug Monitoring of Ivacaftor, Lumacaftor, Tezacaftor, and Elexacaftor in Cystic Fibrosis: Where Are We Now?

  2022cites this paper
• 6 Monate Zulassung von Kaftrio® in Deutschland – erste Erfahrungen aus dem „wahren Leben“ von Menschen mit CF

  2022influential citation
• Structural Comparative Modeling of Multi-Domain F508del CFTR

  2022cites this paper
• Quantitation of cystic fibrosis triple combination therapy, elexacaftor/tezacaftor/ivacaftor, in human plasma and cellular lysate.

  2022cites this paper
• Update on Clinical Outcomes of Highly Effective Modulator Therapy.

  2022cites this paper
• In silico drug repositioning on F508del-CFTR: A proof-of-concept study on the AIFA library.

  2021cites this paper
• Emerging non-pulmonary complications for adults with cystic fibrosis.

  2021cites this paper
• Structural comparative modeling of multi-domain ΔF508 CFTR

  2021cites this paper
• Mental status changes during elexacaftor/tezacaftor / ivacaftor therapy.

  2021cites this paper
• TMEM16A/ANO1: Current Strategies and Novel Drug Approaches for Cystic Fibrosis

  2021cites this paper
• Optimizing sexual and reproductive health across the lifespan in people with cystic fibrosis

  2021cites this paper
• Management of Individual Patient Expectations When Starting with Highly Effective CFTR Modulators

  2021cites this paper
• Triple combination cystic fibrosis transmembrane conductance regulator modulator therapy in the real world – opportunities and challenges

  2021cites this paper
• Review of CFTR modulators 2020

  2021cites this paper
• New Therapies to Correct the Cystic Fibrosis Basic Defect

  2021cites this paper
• Elexacaftor-tezacaftor-ivacaftor: The new paradigm to treat people with cystic fibrosis with at least one p.Phe508del mutation.

  2021cites this paper
• Sexual and reproductive health in cystic fibrosis

  2020cites this paper
• Development of elexacaftor – tezacaftor – ivacaftor: Highly effective CFTR modulation for the majority of people with Cystic Fibrosis

  2020cites this paper
• Men's health in the modern era of cystic fibrosis.

  2020cites this paper
• Real-World Safety of CFTR Modulators in the Treatment of Cystic Fibrosis: A Systematic Review

  2020influential citation
• A current review of the safety of cystic fibrosis transmembrane conductance regulator modulators

  2020cites this paper
• Heterogeneity in Reported Side Effects Following Initiation of Elexacaftor-Tezacaftor-Ivacaftor: Trikafta Experiences at a Quaternary CF Care Center

  year unknowncites this paper